ERIC I RICHMAN
CIK 1313876 · CHIEF EXECUTIVE OFFICER · last filed 2025-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$893.0K
Companies
4
Total Filings
55
Lifetime Open-Market Net
-$414.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GANX | Director | 292,458 | $1.73 | $506.0K | $102.8K | 9 | 2025-06-25 |
| NeuBase Therapeutics, Inc. (NBSE) Delisted | Director | 3,585 | $0.38 | $1.4K | $96.4K | 7 | 2022-09-12 |
| ADMA | Director | 44,030 | $8.79 | $387.0K | $106.3K | 11 | 2020-03-03 |
| Altimmune, Inc. (PIP) Delisted | Director | 45,490 | — | — | -$719.7K | 24 | 2016-11-23 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-09-17 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-17 | GANX | Exer (M) | +4,922 | $38.7K | EDGAR |
| 2021-04-27 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Buy (P) | +5,000 | $25.0K | EDGAR |
| 2020-09-11 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-04 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Buy (P) | +10,833 | $65.0K | EDGAR |
| 2020-03-03 | ADMA | Grant (A) | +7,500 | $0 | EDGAR |
| 2019-07-16 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | +25,247 | $0 | EDGAR |
| 2019-03-15 | ADMA | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | ADMA | Grant (A) | — | $0 | EDGAR |
| 2018-06-11 | ADMA | Buy (P) | +5,230 | $25.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.